Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - anti-epilettiċi, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - drogi oħra tas-sistema nervuża - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin aspart - diabetes mellitus - drogi użati fid-dijabete - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

baxter holding b.v. - insulin human (rdna) - diabetes mellitus - drogi użati fid-dijabete - inpremzia is indicated for the treatment of diabetes mellitus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - amino acid metaboliżmu, Żbalji inborn - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - aġenti antineoplastiċi - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

n.v. organon - desloratadine, pseudophedrine sulfate - rinite allerġika staġjonali - preparazzjonijiet imnieħer - trattament sintomatiku ta 'rinite allerġika staġjonali meta jkun akkumpanjat minn konġestjoni nażali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belimumab - lupus eritematoso, sistemiku - immunosoppressanti - benlysta huwa indikat bħala terapija add-on f'pazjenti b'età ta ' 5 snin u akbar bi attiva, awtoantikorpi pożittivi lupus eritematosus sistemika (sle) bil-livell għoli ta'attività tal-marda (e. , pożittivi kontra dsdna u baxxa jikkumplimentaw) minkejja terapija standard. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - midazolam - epilessija - psikolettiċi - kura ta 'attakki fit-tul, akuti u konvulsivi fi trabi, tfal żgħar, tfal u adolexxenti (minn tliet xhur sa inqas minn 18-il sena). buccolam għandu jintuża biss mill-ġenituri / dawk li jieħdu ħsiebhom fejn il-pazjent ikun ġie dijanjostikat li jkollhom l-epilessija. għat-trabi ta 'bejn tlieta u sitt xhur ta' l-età, it-trattament għandu jiġi fi sptar fejn il-monitoraġġ huwa possibbli u huwa disponibbli tagħmir ta ' risuxxitazzjoni.